Compare DSX & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSX | ALLO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 252.9M |
| IPO Year | 2005 | 2018 |
| Metric | DSX | ALLO |
|---|---|---|
| Price | $1.66 | $1.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 578.1K | ★ 2.7M |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 231.99 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $218,560,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.40 | $100.00 |
| P/E Ratio | $11.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.27 | $0.86 |
| 52 Week High | $2.04 | $3.78 |
| Indicator | DSX | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 47.06 |
| Support Level | $1.67 | $1.30 |
| Resistance Level | $1.73 | $1.52 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 4.78 | 20.37 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation, the services provided by the vessels are similar and all operate under the same economic environment.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.